Activin- and myostatin-binding glycoprotein
Follistatin-315
Follistatin-315 has an app half-life of 240 hours (about 10 days); no half-life measured in people was identified in PubMed or ClinicalTrials.gov queries.
Follistatin-315 after one dose: 50% at ~240 h, 25% at 480 h, 12.5% at 720 h.
Drawn from the half-life in the app's model, ~240 h. The model's figures
- Compound
- Follistatin-315
- Symbol
- FST
- Family
- Growth hormone peptides
- Parts
- 13
- References
- 12
- Checked
- Last reviewed . Sources are listed below.
Overview
Sources in this part
Sugino and colleagues (Journal of Biological Chemistry, 1993) describe follistatin as an activin-binding protein with two polypeptide core sequences, of 315 amino acids (FS-315) and 288 amino acids (FS-288), that originate from alternatively spliced mRNA.1 Mendell and colleagues (Molecular Therapy, 2015) write that two follistatin isoforms are generated by alternative splicing and initially translated as FS317 and FS344, and that cleavage of a 29 amino acid signal peptide gives FS288 and FS315.2 In that paper the FS344 variant "includes a C-terminal acidic region that undergoes peptide cleavage to generate the serum circulating, nontissue binding, FS315 isoform".2 The same authors state that "FS315 more reliably targets skeletal muscle", and they describe FS288 as working with activin and inhibins in the hypothalamic pituitary-gonadal axis.2
The app lists one route for follistatin-315, subcutaneous injection (SubQ), and grades the evidence as emerging. The app's notes attribute an extended circulating half-life to lower heparan sulfate proteoglycan binding than the FS-288 isoform, and the sections below set out what the sources read report on each part of that statement.
The FS344 gene therapy trials identified in the queries described here delivered the gene in an adeno-associated virus (AAV1) vector into muscle, so their results are reported as gene therapy results and are not read as results of injected follistatin-315 protein.2,3 No trial of injected follistatin-315 protein in people was identified in the PubMed and ClinicalTrials.gov queries used, and none of the sources read measures the app's half-life, bioavailability or time-to-peak figures. The one report of people injecting follistatin under the skin that these queries returned is a retrospective case series of eye disease after high-dose follistatin-344, described under side effects below.4
How it works
In laboratory work on follistatin purified from porcine ovaries, Sugino and colleagues report that all six molecular forms had almost the same activin binding, with a dissociation constant (Kd) of 540 to 680 pM.1 They report that FS-288 bound to heparan sulfate-Sepharose "but FS-315 did not", and that FS-315 had no affinity for the rat granulosa cell surface.1 In rat anterior pituitary culture, the concentration giving half the effect (ED50) for suppressing follicle-stimulating hormone release was 2 ng/ml for FS-288 and 20 ng/ml for FS-315.1 This was work on purified protein and cultured cells, not on people.1 A review by Al-Zaidy and colleagues (Journal of Neuromuscular Diseases, 2015, Nationwide Children's Hospital) says follistatin's ability "to interact with the pituitary activin-inhibin axis and suppress the secretion of follicle-stimulating hormone (FSH) called for caution in its clinical applicability".5 The same review says FS315 "is serum-based, and has a 10-fold lower affinity to activin compared to FS288", a statement that differs from the near-equal activin binding that Sugino and colleagues report for the purified forms.5,1 Mendell and colleagues call follistatin "a potent myostatin antagonist" and cite mouse and macaque work as the basis for the human trials.2 In the macaque study (Kota and colleagues, Science Translational Medicine, 2009), AAV1-FS344 injected into the quadriceps "induced pronounced and durable increases in muscle size and strength", an animal result that the Becker trial below did not reproduce as diffuse muscle growth.7,2
Half-life and pharmacokinetics
Values from the Milligram app's model.
- Half-life
- ~240 h
- Bioavailability
- 70%
- Typical dose
- 100–300 mcg/day
- Route
- SubQ
- Time to peak
- ~12 h
Sources in this part
The second column of the table holds the app's own figures, shown beside what the sources read report.
| Parameter | App's figure | Reported in the sources |
|---|---|---|
| Half-life | About 10 days (240 hours) | No half-life measured in people was identified; Datta-Mannan and colleagues write that the "intrinsic PK/PD properties of native FST315 are poorly suited for acting as a parentally administered biotherapeutic with broad systemic effects", and the PubMed record read gives no half-life figure for the native protein6 |
| Bioavailability | 70% | No bioavailability measurement was identified in the sources read |
| Time to peak | About 12 hours | No time to peak was identified in the sources read |
| Duration of activity and model | 504 hours (21 days); one-compartment model; volume of distribution and absorption rate not set | Not measured in the sources read |
The app's notes tie the 10-day half-life to lower heparan sulfate proteoglycan binding. Datta-Mannan and colleagues fused FST315 to a murine IgG1 Fc and removed its intrinsic heparan sulfate-binding activity, and report that the engineered variant had "~100- and ~1600-fold improvements in terminal half-life and exposure, respectively".6 The Datta-Mannan authors are listed at Lilly Research Laboratories, and the record read holds no funding statement.6 Because both changes were made together and the record read describes the variant's effect in mouse models, it does not separate the effect of losing heparan sulfate binding from the effect of the Fc fusion, and it gives no human half-life.6
Human studies
The table lists the human reports identified, and none of them tests injected follistatin-315.
| Study and year | Design | People | Dose and length | Main result |
|---|---|---|---|---|
| Mendell and colleagues, Molecular Therapy 2015 (Becker muscular dystrophy)2 | Single-site, dose-ascending gene therapy trial, registered as non-randomised and unmasked; supported by Parent Project Muscular Dystrophy2,8 | Six ambulatory men with Becker muscular dystrophy and knee extensor weakness2 | AAV1.CMV.FS344 into both quadriceps: 3 × 1011 vg/kg per leg in three men (followed 1 year) or 6 × 1011 vg/kg per leg in three men (followed 6 months)2 | Six-minute walk change of +58, +125 and +9 m (3 × 1011 group) and +108, +29 and -14 m (6 × 1011 group); no consistent rise in quadriceps strength; no significant adverse events related to gene transfer2 |
| Mendell and colleagues, Molecular Therapy 2017 (sporadic inclusion body myositis)3 | Open gene therapy trial with an exercise regimen, compared with a cohort of untreated sporadic inclusion body myositis patients (n = 8) followed in the authors' Neuromuscular Clinic and matched for age, gender and baseline 6-minute walk; authors' ties to a licensee disclosed3,8 | Six subjects with sporadic inclusion body myositis, ambulatory and relatively mildly affected3 | rAAV1.CMV.huFS344, 6 × 1011 vg/kg per leg into both quadriceps; annualised to a median 1-year change3 | Six-minute walk +56.0 m/year in six treated people against -25.8 m/year in eight untreated clinic patients (p = 0.01); four of six rose 58-153 m and two were minimally improved (5-23 m); secondary outcomes at 1 year: ascending stairs improved for all patients and four improved in Timed Up and Go; no adverse events related to gene therapy; two subjects had unrelated serious events after falls or accidents3 |
| Registry entry NCT02354781, results posted 2020 (Duchenne muscular dystrophy)9 | Phase 1/2, single group, no masking; lead sponsor the investigator, with Milo Therapeutics as an industry collaborator9 | Three participants enrolled; the description planned six9 | 2.4E12 vg/kg in total (1.2E12 vg/kg per limb) by multiple intramuscular injections; follow-up up to 2 years9 | Deaths 0 of 3, serious adverse events 1 of 3 (head injury from a fall), other adverse events 3 of 3; muscle biopsies were cancelled because of disease progression9 |
| Dağ and colleagues, International Ophthalmology 2020 (eye disease after follistatin-344 injections)4 | Retrospective case series from one institution4 | Eleven male bodybuilding athletes, mean age 36.8 ± 8.1 years, who attended with decreased visual acuity4 | Complete 1 mg vials of follistatin-344 injected subcutaneously in the abdomen; one previous injection in eight, several in three4 | Central serous chorioretinopathy: subretinal fluid cleared after an average of 2.3 ± 0.7 months in the eight with one injection; recurrence in the three with several4 |
Deeper analysis: the Becker muscular dystrophy trial (Mendell, 2015)
Mendell and colleagues, of the Center for Gene Therapy at Nationwide Children's Hospital in Columbus, Ohio, reported a phase 1/2a trial of AAV1.CMV.FS344 in Becker muscular dystrophy in Molecular Therapy in 2015.2 Six men were treated in two dose cohorts, with four injections into each of three quadriceps muscle groups, after the authors chose FS344 "to avoid potential binding to off target sites".2 Participants were not on immunosuppressive therapy at recruitment but "were placed on prednisone 1 month prior to AAV1.CMV.FS344 injections as a precaution against an immune response to AAV capsid", and prednisone was tapered off by day 60.2 The paper names the 6-minute walk test as the primary outcome, whereas the registry entry lists safety as the primary outcome and muscle function and strength testing as secondary.2,8 The walk distance rose in five of six men (+58, +125, +9, +108 and +29 m) and fell by 14 m in one, and the authors describe the 9 m change as one they "would not consider this outside the range of variability for the BMD population, based on previous clinical experience".2 They write that "There was no apparent difference in functional outcome between low and high dose, with two of three patients improving in each cohort", and that no consistent quadriceps strength increase was seen in either cohort.2 Their stated explanation is "We believe that the greatest obstacle to gene expression-related improvement was muscle fibrosis", and they report only focal, not diffuse, muscle enlargement.2 One patient refused a second muscle biopsy and another had severe fibrosis at the biopsy site, "limiting interpretation".2 The authors also report that connective tissue "was significantly decreased in posttreatment biopsy samples from all patients", and they count this among the histological changes they say corroborated benefit.2 On safety, the authors report "no significant adverse events during this trial that were related to gene transfer", and that "pituitary-gonadal hormone levels (FSH, LH, estrogen, testosterone (Supplementary Figure S1)) remained normal throughout the trial".2 One participant's immune response is the exception they describe: "Patient 06 showed early and significant elevation of immune response to follistatin that was not present prior to gene transfer".2 Among the limitations in the text, the authors note that "no comparative natural history data of the 6MWT in BMD patients is available", and the registry lists a single group with no masking.2,8 Funding: "The Parent Project Muscular Dystrophy supported the Clinical Trial", and the record lists a National Institute of Child Health and Human Development grant, U54 HD066409.2 Sponsor ties: one author, B.K. Kaspar, "had intellectual property filed through Nationwide Children's Hospital and an equity interest related to work that is licensed to Milo Biotechnology" and is a paid consultant for Milo, the paper states that "The relationships are managed through a conflict management plan", and the same paper also states "The authors declare no conflict of interest".2
Deeper analysis: the inclusion body myositis trial (Mendell, 2017)
Mendell and colleagues reported six people with sporadic inclusion body myositis who each received rAAV1.CMV.huFS344 into both quadriceps, with an exercise regimen, in Molecular Therapy in 2017.3 The primary outcome was the 6-minute walk distance, annualised to a median 1-year change: +56.0 m/year in treated subjects against -25.8 m/year (p = 0.01) in untreated subjects (n = 8) matched for age, gender and baseline measures.3 Four of six rose by 58 to 153 m and two were "minimally improved (5-23 m)".3 Secondary motor outcomes at 1 year are reported as ascending stairs improved for all patients and four patients improved in Timed Up and Go, and the walk data of subject 3 were included only up to the point of his fall.3 The authors say exercise "appeared to influence the outcome" and that "the difference was striking between the exercise cohort (subjects 2,4, 5, and 6) and the non-exercise cohort (subjects 1 and 3)", while also writing that all patients improved on outcome measures and that, as to efficacy entirely related to exercise, "we believe this to be highly unlikely" given prior reports of exercise alone failing to improve function.3 They also write that a glucocorticoid effect "received by sIBM subjects for about 60 days, in the presence of exercise and follistatin upregulation, could have influenced outcomes".3 On safety, "No adverse events (AEs) or serious AEs (SAEs) were encountered related to gene therapy", but subject 3 had a fall causing "an SAE of a concussion and torn hamstring", and subject 4 had two serious events, a biking accident and a fall that needed several weeks of rehabilitation.3 They report no changes in pituitary-gonadal hormone levels (FSH, LH, estrogen or testosterone).3 The authors' stated limits include that the participants "were ambulatory and relatively mildly affected", that the paradigm "must also be extended to include females", and that "Questions continue regarding how long the treatment benefit will persist".3 The paper states that "The Parent Project Muscular Dystrophy supported the clinical trial", that staff and some materials came from the Wellstone Muscular Dystrophy Research Center (NICHD, NIH grant U54 HD066409) and that Jesse's Journey supported some staff, and the conflict statement repeats that B.K. Kaspar holds "an equity interest related to work that is licensed to Milo Biotechnology" and is "a paid consultant for Milo", with the relationships "managed through a conflict management plan".3
Deeper analysis: the Duchenne registry entry (NCT02354781)
The registry entry describes a phase 1/2 trial of AAV1.CMV.huFS344 at a total dose of 2.4E12 vg/kg in Duchenne muscular dystrophy, with safety as the primary outcome and walk distance as a secondary outcome.9 Its status is completed, three participants were enrolled, and the posted results list no deaths among the three, one serious adverse event (head injury from a fall) and other adverse events in all three.9 The results note that "All muscle biopsies were canceled per PI discretion due to the disease progression of each participant".9 The lead sponsor is the investigator, Jerry R. Mendell, with the Duchenne Alliance and Milo Therapeutics (class: industry) as collaborators.9 No journal report of this entry's results was read.
Deeper analysis: eye disease after follistatin-344 injections (Dağ, 2020)
Dağ and colleagues, of Diyarbakir Gazi Yasargil Research and Training Hospital in Turkey, reported 11 bodybuilding athletes with central serous chorioretinopathy (CSCR) after high-dose subcutaneous follistatin-344 in International Ophthalmology in 2020.4 All 11 were men with a mean age of 36.8 ± 8.1 years, ten had CSCR in one eye and one in both, and each had injected "complete 1 mg vials" subcutaneously in the abdomen.4 In the eight with one previous injection, subretinal fluid "completely disappeared after an average of 2.3 ± 0.7 months", and CSCR recurred in the three with multiple injections.4 The authors conclude that "Follistatin-344 injection can be considered as a risk factor for CSCR".4 The design is "a retrospective case series from one institution" of patients who presented with the eye condition, so it gives no count of people who injected follistatin-344 without it and cannot give a rate.4 The product was labelled follistatin-344, not follistatin-315, and the record read holds no funding statement and no analysis of the content of the injected material.4
Other human registry entries
A registry entry from Minicircle (class: industry) describes an early phase 1, single-group, unmasked study of a plasmid gene therapy combining klotho and follistatin, given by subcutaneous injection into abdominal fat deposits to healthy adults, with 14 participants and a status of completed.10 Its primary outcomes include serum follistatin concentration and the number of participants with treatment-emergent adverse events, and no results from it were read.10
Doses reported in studies and on labels
The gene therapy doses below are in vector genomes per kilogram and cannot be converted to the app's micrograms per day of protein.
| Source | Dose as reported | Route and duration | People |
|---|---|---|---|
| Mendell 20152 | 3 × 1011 vg/kg per leg, then 6 × 1011 vg/kg per leg, of AAV1.CMV.FS3442 | Intramuscular, quadriceps of both legs; followed 1 year and 6 months2 | Three men per dose; Becker muscular dystrophy2 |
| Mendell 20173 | 6 × 1011 vg/kg per leg of rAAV1.CMV.huFS3443 | Intramuscular, quadriceps of both legs; outcomes annualised to 1 year3 | Six people with sporadic inclusion body myositis3 |
| Registry NCT015193498 | Cohorts of 2E11 vg/kg (one quadriceps), 3E11 vg/kg per quadriceps and 6E11 vg/kg per quadriceps of rAAV1.CMV.huFollistatin344; the entry labels the 6E11 cohort "Low Dose"8 | Intramuscular; safety time frame 2 years8 | Registry lists 15 actual enrolments, whereas each of the two papers reports six treated people8,2,3 |
| Registry NCT023547819 | 2.4E12 vg/kg in total (1.2E12 vg/kg per limb) of rAAV1.CMV.huFollistatin3449 | Multiple intramuscular injections to gluteal, quadriceps and tibialis anterior muscles; up to 2 years of follow-up9 | Three people with Duchenne muscular dystrophy enrolled9 |
| Dağ 20204 | Complete 1 mg vials of follistatin-344, as the patients reported4 | Subcutaneous, abdomen; a single injection in eight and multiple injections in three4 | Eleven men who presented with eye disease4 |
| The app | 100 to 300 mcg/day | SubQ | None of the sources read gives this dose or a study using it |
No drug label for follistatin was identified, so no label dose is listed.
Side effects reported
Sources in this part
In the Becker trial the authors report no significant adverse events related to gene transfer, and in the inclusion body myositis trial no adverse events or serious adverse events related to gene therapy.2,3 In the Duchenne registry entry, one of three participants had a serious adverse event (head injury from a fall) and three of three had other adverse events, with no deaths.9 Among the other adverse events listed in that entry are increased muscle weakness and a compression fracture, each in one participant.9 The Dağ case series reports central serous chorioretinopathy in 11 bodybuilding athletes after high-dose subcutaneous follistatin-344, with recurrence in three who had injected more than once.4 These gene therapy trials enrolled 6, 6 and 3 people, and none of them is a study of injected follistatin-315.2,3,9
Bloodwork and markers
Sources in this part
The app lists FSH as the marker to monitor for follistatin-315. Al-Zaidy and colleagues say follistatin's interaction with the pituitary activin-inhibin axis and suppression of FSH secretion "called for caution".5 Mendell and colleagues write that safety concerns were raised about "follistatin dysregulation of pituitary gonadotropins, especially follicle-stimulating hormone (FSH) and luteinizing hormone (LH)".2 In the Becker trial, serum chemistry and haematology were assessed at baseline and on days 7, 14, 30, 60, 90 and 180 and at 1 year, including "serum hormones (FSH, LH, testosterone, estrogen)", and the hormone levels "remained normal throughout the trial".2 The inclusion body myositis trial measured the same hormones and reports no changes in pituitary-gonadal hormone levels.3 These FSH findings come from FS344 gene delivery into muscle in six people per trial, and they are not measurements after injected follistatin-315.2,3
Regulatory and anti-doping status
Sources in this part
The World Anti-Doping Agency's 2026 Prohibited List places follistatin in class S4.3 of the hormone and metabolic modulators, under myostatin inhibitors, with the entry "Myostatin-binding proteins (e.g. follistatin, myostatin propeptide)".11 Class S4 is marked "PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION)", and the list states that those in classes S4.3 and S4.4 are non-specified substances.11 A DailyMed query for "follistatin" returned no drug labels, and no regulatory approval of follistatin-315 was identified in the sources read.11
What is not known
Sources in this part
- No half-life, bioavailability or time to peak for follistatin-315 in people was identified, so the app's figures of 240 hours, 70% and 12 hours have no measurement in the sources read to compare with.
- The sources disagree on how FS-315 compares with FS-288: Sugino and colleagues report near-equal activin binding for purified forms, and Al-Zaidy and colleagues write of a 10-fold lower affinity to activin.
- Whether injected follistatin-315 reaches muscle, and at what dose, was not reported by any source read; the muscle effects described come from gene delivery of FS344 in six, six and three people.
- The walk-distance gains came from open trials of six people each: the Becker trial is listed as a single group with no masking and its authors write that no comparative natural history data of the 6MWT in BMD patients is available, while the inclusion body myositis trial compared its six treated people with eight untreated patients followed in the authors' clinic, and its authors write that exercise appeared to influence the outcome and that a glucocorticoid effect could have influenced outcomes, while judging an exercise-only explanation highly unlikely.
- The content of the injected products in the Dağ case series was not described in the record read, and its label said follistatin-344.
- A phase 1 trial of an intradermal, cell-derived formulation containing follistatin among other factors (Zimber and colleagues, 2011) tested a mixture, not follistatin-315, so its hair-growth result is not a result for follistatin-315.12
Frequently asked questions
What is the half-life of follistatin-315?
The app lists a half-life of about 240 hours (about 10 days), and no half-life measured in people was identified in the sources read. Datta-Mannan and colleagues describe the intrinsic pharmacokinetic properties of native FST315 as poorly suited to a parenterally administered biotherapeutic, and the record read gives no figure for it.6
What is the difference between follistatin-315 and follistatin-288?
Follistatin-315 and follistatin-288 are two forms of follistatin of 315 and 288 amino acids that originate from alternatively spliced mRNA.1 In purified-protein and cell work, FS-288 bound heparan sulfate-Sepharose but FS-315 did not, and FS-288 was more potent at suppressing FSH release from rat pituitary culture (ED50 2 ng/ml against 20 ng/ml).1
What is the difference between follistatin-315 and follistatin-344?
Is follistatin banned by WADA?
Does follistatin-315 change FSH?
Has follistatin-315 been tested in people?
No trial of injected follistatin-315 protein in people was identified in the PubMed and ClinicalTrials.gov queries used.2 Gene therapy delivering FS344 into muscle was tested in 6 men with Becker muscular dystrophy and 6 people with sporadic inclusion body myositis, and a registry entry lists 3 people with Duchenne muscular dystrophy.2,3,9
What side effects have been reported with follistatin?
The Becker trial reports "no significant adverse events" related to gene transfer and the inclusion body myositis trial reports no adverse events or serious adverse events related to gene therapy, while the Duchenne registry entry lists one serious adverse event (head injury from a fall) and other adverse events in all three participants.2,3,9 A case series of 11 bodybuilding athletes reports central serous chorioretinopathy after high-dose subcutaneous follistatin-344, with recurrence in three who injected more than once.4
Is follistatin-315 approved as a drug?
No drug label for follistatin was identified in a DailyMed query, and no approval of follistatin-315 was identified in the sources read.
More in Growth hormone peptides
References
- Sugino K, et al. Molecular heterogeneity of follistatin, an activin-binding protein. Higher affinity of the carboxyl-terminal truncated forms for heparan sulfate proteoglycans on the ovarian granulosa cell. J Biol Chem 1993. PMID 8340384
- Mendell JR, et al. A phase 1/2a follistatin gene therapy trial for becker muscular dystrophy. Mol Ther 2015. PMID 25322757
- Mendell JR, et al. Follistatin Gene Therapy for Sporadic Inclusion Body Myositis Improves Functional Outcomes. Mol Ther 2017. PMID 28279643
- Dağ U, et al. Central serous chorioretinopathy associated with high-dose follistatin-344: a retrospective case series. Int Ophthalmol 2020. PMID 32671599
- Al-Zaidy SA, et al. Follistatin Gene Therapy Improves Ambulation in Becker Muscular Dystrophy. J Neuromuscul Dis 2015. PMID 27858738
- Datta-Mannan A, et al. An engineered human follistatin variant: insights into the pharmacokinetic and pharmocodynamic relationships of a novel molecule with broad therapeutic potential. J Pharmacol Exp Ther 2013. PMID 23249626
- Kota J, et al. Follistatin gene delivery enhances muscle growth and strength in nonhuman primates. Sci Transl Med 2009. PMID 20368179
- Nationwide Children's Hospital. Follistatin Gene Transfer to Patients With Becker Muscular Dystrophy and Sporadic Inclusion Body Myositis. ClinicalTrials.gov NCT01519349. NCT01519349
- Mendell JR. Clinical Intramuscular Gene Transfer of rAAV1.CMV.huFollistatin344 Trial to Patients With Duchenne Muscular Dystrophy. ClinicalTrials.gov NCT02354781. NCT02354781
- Minicircle. Safety and Efficacy of Klotho and Follistatin Gene Therapy. ClinicalTrials.gov NCT07285629. NCT07285629
- World Anti-Doping Agency. World Anti-Doping Code International Standard: Prohibited List 2026. WADA list
- Zimber MP, et al. Hair regrowth following a Wnt- and follistatin containing treatment: safety and efficacy in a first-in-man phase 1 clinical trial. J Drugs Dermatol 2011. PMID 22052313